Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AAPL$329.72-2.18(-0.66%)Apple Readies Launch of AI-Powered Health App7:42:21 PM ETAMGN$455.00-6.26(-1.36%)Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say7:30:56 PM ETAAPL$329.72-2.18(-0.66%)Apple: 3 Key Takeaways for Long-Term Investors7:28:50 PM ETAMD$508.90+25.00(+5.17%)Here's why AMD's stock is rising — and sending a confident message about the AI trade7:17:00 PM ETAMD$508.90+25.00(+5.17%)AMD: Expensive For A Reason7:15:26 PM ETGOOG$277.20-0.80(-0.29%)Google responds to political backlash over removing search from schools that ban AI7:10:07 PM ETPLTR$172.83-2.57(-1.47%)Jim Cramer Says the Executioner Is “Axing Palantir and Apple.” What Investors Should Make of It7:09:17 PM ETABBV$285.06-0.94(-0.33%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:08:52 PM ETTSLA$391.37-12.49(-3.09%)Tesla misled South Korean customers about automated-driving tech, consumer group alleges7:03:18 PM ETABBV$285.06-0.94(-0.33%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:01:03 PM ETAMD$508.90+25.00(+5.17%)Advanced Micro (AMD) Reports Q3 Earnings: What Key Metrics Have to Say7:01:02 PM ETAMD$508.90+25.00(+5.17%)UPDATE 7-AMD forecast eases AI spending fears as data-center sales surge7:00:54 PM ETAMD$508.90+25.00(+5.17%)AMD: The Odds Are Getting Better, But The Bet Still Isn't Worth It (Upgrade)7:00:06 PM ETHSBC$84.63+0.14(+0.17%)HSBC Holdings: 3 Key Takeaways for Long-Term Investors7:00:02 PM ETAMD$508.90+25.00(+5.17%)Advanced Micro Devices (AMD) Q3 Earnings and Revenues Top Estimates6:51:30 PM ETDIS$114.07-0.11(-0.10%)Why Walt Disney (DIS) Outpaced the Stock Market Today6:46:07 PM ETHD$332.32-1.34(-0.40%)Home Depot (HD) Stock Falls Amid Market Uptick: What Investors Need to Know6:46:05 PM ETAMD$508.90+25.00(+5.17%)AMD Q3: Profits Are Booming, Cash Is Disappearing (Rating Downgrade)6:45:12 PM ETCRWD$243.44-1.24(-0.51%)CrowdStrike's new kill switch can stop rogue AI agents in their tracks, CEO says6:37:07 PM ETAMD$508.90+25.00(+5.17%)AMD Soars After Huge Guidance News6:30:29 PM ETAMGN$455.00-6.26(-1.36%)Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates6:15:56 PM ETANET$186.80+16.89(+9.94%)Arista Networks (ANET) Q3 Earnings and Revenues Beat Estimates6:15:53 PM ETAMD$508.90+25.00(+5.17%)AMD: Don't Chase The Record Quarter6:10:20 PM ETAMD$508.90+25.00(+5.17%)BRIEF-AMD CEO - Now Expect Revenue to Grow More Than 80% in 20276:02:02 PM ET

RARE · NASDAQ

Ultragenyx Pharmaceutical Inc.

$15.72 -0.60 (-3.68%)

Company overview

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its marketed biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for children and adults with Mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$1.5B
Employees
1,294
Headquarters
Novato, CA
Website
ultragenyx.com
CEO
Emil D. Kakkis
Listed
January 31, 2014
P/E
-2.59
Dividend yield
0.00%

Company financials

Revenue
$669M
Gross profit
$559M
Operating income
-$562M
EBITDA
-$514M
Net income
-$609M
EPS
-$6.11
Total assets
$1.3B
Total debt
$1.2B
Gross margin
83.57%
Net margin
-91.03%
Earnings yield
-38.67%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

11.7818.2124.6531.0937.52
RARE 1D NASDAQ O16.29H16.44L15.85C16.30+0.20 (+1.24%)Vol4.84M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Stock news Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx Q3 revenue rises, net loss narrows Reuters
RAREUltragenyx Pharmaceutical Inc. Stock news BRIEF-Ultragenyx Q3 EPS USD -1.16 Reuters
RAREUltragenyx Pharmaceutical Inc. Press release Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Press release Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Press release AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 Amgen (NASDAQ: AMGN) today announced plans to present new data across its portfolio, including in rare and other serious autoimmune diseases. PR Newswire
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Stock news RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Stock news Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Press release Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Stock news Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE) Defense World
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million Proactive Investors
RAREUltragenyx Pharmaceutical Inc. Press release Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation Zacks Investment Research
RAREUltragenyx Pharmaceutical Inc. Press release Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) GlobeNewswire
RAREUltragenyx Pharmaceutical Inc. Stock news Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts Defense World
RAREUltragenyx Pharmaceutical Inc. Press release JAGUAR URANIUM REPORTS RARE EARTH OXIDES ASSOCIATED WITH URANIUM-PHOSPHATE-VANADIUM MINERALIZATION AT THE BERLIN ASSET IN COLOMBIA PR Newswire
RAREUltragenyx Pharmaceutical Inc. Press release ULTRA-RARE MCA CENTENAIRE, MONACO’S FIRST SUPERCAR, OFFERED GlobeNewswire
See more
FAQ

Questions about Ultragenyx Pharmaceutical Inc.

What does Ultragenyx Pharmaceutical Inc. do?
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its marketed biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for children and adults with Mucopolysaccharidosis VII; Dojolvi for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for homozygous familial hypercholesterolemia.
What is RARE's market cap?
Ultragenyx Pharmaceutical Inc. (RARE) is a listed stock with a live quote. The latest market cap on this page is $1.5B.
Where is Ultragenyx Pharmaceutical Inc. headquartered?
Ultragenyx Pharmaceutical Inc. is headquartered in Novato, CA.
How do I get RARE news from the API?
Call GET /v1/news?tickers=RARE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does RARE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for RARE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the RARE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs